1. Home > Latest Topics >

Question 8: Cost-effectiveness of IV-PO switch

20 June, 2018

Question 8
Cost-effectiveness of treatment strategies is gaining in importance. Can you comment on the relative cost-effectiveness of LRTI antimicrobial therapies, with specific reference to the CAPITAL study, and savings associated with early IV-PO switch therapy?


LATEST TOPICS

Managing Infectious Diseases in Emergency Medicine: A Specialist’s Approach
10 April, 2024
Advancing standardised diagnosis and treatment of acute infectious disease: Insights from an expert in theory–technique integration
08 April, 2024
Managing severe infections: Practical approaches for antibiotic use, including combination therapy
05 March, 2024
Updating Traditional Approaches: Expert Insights on Addressing Urinary Tract Infections
26 February, 2024
Antibiotic resistance may be driven by diverse factors, including extreme climatic events
14 February, 2024

RELATED ARTICLES

Professional Insights: Navigating Optimal Diagnosis and Treatment of Infectious Diseases in the Emergency Department
05 February, 2024
Community-acquired pneumonia: Updates in local treatment strategy and clinical experience with levofloxacin
07 October, 2021
Innovator versus Generic Antibiotics: Clinical Effectiveness in Pneumonia
23 October, 2023
Advancing standardised diagnosis and treatment of acute infectious disease: Insights from an expert in theory–technique integration
08 April, 2024
Antimicrobial resistance in respiratory tract infections: Current trends and strategies
06 August, 2021